Immunotherapy Clinical Trials for Lung Cancer: Your Guide

July 28, 2026

Immunotherapy Clinical Trials for Lung Cancer: Your Guide

Patient and oncologist discussing immunotherapy trial

Immunotherapy clinical trials for lung cancer are actively recruiting right now across the United States, and for many patients, they are a real option, not a last resort. If you or someone you love has been diagnosed, the first move is clear: check clinicaltrials.gov, request your tumor biomarker report from your oncologist, and ask about trial eligibility at your next appointment.

Trials are open across multiple stages and histologies, including early-stage, locally advanced, and metastatic non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression, KRAS mutations, or who have completed chemoradiation for Stage III disease are among those most commonly eligible right now. Every trial operating in the U.S. carries FDA oversight and Institutional Review Board (IRB) protection, and many provide more frequent monitoring than standard community oncology care.

Here is what to do immediately:

Request your biomarker report. Ask your oncologist for tumor molecular profiling results, including PD-L1, KRAS G12C, EGFR, ALK, and TMB. These results determine which trials you may enter.
Search clinicaltrials.gov. Use your diagnosis, stage, and biomarker status as filters. Save the NCT number of any trial that looks relevant.
Contact the NCI. The NCI lung cancer trial listings catalog trials by type, phase, and treatment approach.
Talk to your oncologist today. Trial eligibility windows can close. The sooner you ask, the more options remain open.

Pro Tip: Ask your oncologist specifically: “Am I a candidate for any immunotherapy clinical trials?” Many patients wait to be told. You have every right to ask first.

This article is general information, not medical advice. Please confirm your specific situation with your oncologist or a qualified cancer specialist.

Which immunotherapy types are studied for lung cancer?
Why should you consider joining an immunotherapy trial?
How do you find U.S. immunotherapy clinical trials?
What do trial phases mean, and who qualifies?
What does participating in a trial actually look like?
What do trials cost, and who pays?
Questions to ask the trial team and your oncologist
How do you go from finding a trial to actually enrolling?
Why comprehensive cancer centers matter, and how HCRF can help
Key Takeaways
Why we believe every patient deserves a seat at the table
HCRF is here to help you find the right trial
Trusted registries and resources for verified trial listings

Which immunotherapy types are studied for lung cancer?

Understanding the different classes of immunotherapy helps you read trial listings with confidence and ask sharper questions of your care team.

Infographic showing immunotherapy clinical trial phases

PD-1 and PD-L1 inhibitors are the most widely studied class in lung cancer. These checkpoint inhibitors work by blocking a signal that cancer cells use to hide from the immune system. Once that signal is disrupted, T-cells can recognize and attack the tumor. Trials are testing these agents as single therapies, in combination with chemotherapy, and paired with other immunotherapy agents.

Lab technician handling immunotherapy drug vials

CTLA-4 inhibitors take a different approach. Rather than unmasking the tumor, they release the brakes on T-cell activation earlier in the immune response. In lung cancer trials, CTLA-4 agents almost always appear in combination with PD-1/PD-L1 inhibitors, because the two mechanisms work on different checkpoints and can amplify each other’s effect.

Combination regimens are where much of the current research energy sits. Researchers are testing combination immunotherapy and chemotherapy to overcome resistance in metastatic NSCLC, particularly in patients with co-mutations like STK11 or KEAP1 that blunt single-agent checkpoint response. The TROPION-Lung07 trial (NCT05555732), for example, is a Phase 3 study evaluating datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy in first-line non-squamous NSCLC.

Adoptive cell therapies, including CAR-T-like approaches adapted for solid tumors, are still early-stage for lung cancer. Phase 1 trials are exploring feasibility and safety, but these are not yet standard options outside of specialized academic centers.

Cancer vaccines and oncolytic virus therapies aim to teach the immune system to recognize tumor-specific antigens or to use modified viruses to directly kill cancer cells while triggering an immune response. These approaches appear mostly in Phase 1 and Phase 2 trials and represent some of the most forward-looking immunotherapy research for lung cancer today.

Why should you consider joining an immunotherapy trial?

The honest answer is that trials offer something standard care cannot: access to treatments that are not yet approved, often paired with a level of monitoring that goes well beyond what most community oncology practices provide.

Potential benefits include:

Access to investigational agents that may outperform current standard options
Closer, more frequent monitoring, including scheduled labs, imaging, and check-ins that can catch problems early
Chemo-sparing regimens, since some trials are explicitly designed to test whether patients can achieve strong outcomes without conventional chemotherapy
Contribution to research that will help future patients, which many participants find meaningful

Trade-offs to weigh honestly:

Possible unknown side effects, particularly with newer agents or novel combinations
Randomization: in many Phase 3 trials, you may be assigned to the standard-of-care arm rather than the investigational therapy. That arm still receives accepted, proven treatment.
Time and travel: trial visits are more frequent than routine oncology appointments, especially in the first months
Eligibility restrictions: not every patient qualifies, and some trials require specific biomarker profiles

The American Lung Association recommends discussing clinical trial options at diagnosis and at every major treatment decision point, not only when other options have been exhausted. That framing matters. Trials are a parallel path, not a fallback.

Pro Tip: If you are randomized to the control arm of a Phase 3 trial, you are still receiving the current best standard of care, often with more oversight than you would get outside the trial. That is not a consolation prize.

How do you find U.S. immunotherapy clinical trials?

Finding the right trial takes about 30 minutes if you know where to look. Here is a practical, prioritized path:

Start at clinicaltrials.gov. Go to the search bar and enter your diagnosis (e.g., “non-small cell lung cancer”). Then apply filters: condition, phase (Phase 2 or Phase 3 for most patients), recruiting status, and your ZIP code or state. The site allows you to set a geographic radius.
Search the NCI trial pages. The NCI maintains its own curated listings for NSCLC treatment trials, organized by treatment type and phase. These are often easier to read than raw registry entries.
Check the American Lung Association’s resources. The American Lung Association offers patient-facing trial information and can connect you with lung cancer specialists who know the current trial landscape.
Visit major cancer center websites. Academic comprehensive cancer centers, including the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, maintain their own lists of open trials and often have patient navigators who can match you to a study.
Contact a patient navigator. HCRF’s navigation team can help you interpret trial listings, understand eligibility requirements, and connect with the right trial coordinator.

Key filters to use on clinicaltrials.gov:

Biomarker: search for your specific mutation (KRAS G12C, PD-L1 ≥ 50%, EGFR, ALK)
Line of therapy: first-line (no prior treatment) vs. previously treated
Phase: Phase 2 for earlier access, Phase 3 for more established protocols
Geographic radius: set to 50–100 miles initially, then expand if needed

Pro Tip: Save the NCT number of every trial that interests you. That number is your reference point when talking to your oncologist, calling a trial coordinator, or checking back for updates. Write it down or screenshot it.

The Cancer Research Institute also maintains patient-facing educational resources that explain different immune-based approaches and help you understand what you are reading in trial listings.

What do trial phases mean, and who qualifies?

Understanding phases from a patient’s perspective

Phase	Primary Question	What It Means for You
Phase 1	Is this safe? What dose?	Small groups, dose-finding; highest uncertainty, often for patients who have exhausted other options
Phase 1/2	Safety and early signals of response	Expanded cohorts; some efficacy data emerging
Phase 2	Does it work?	Larger groups; response rate and progression-free survival are key endpoints
Phase 3	Is it better than current standard?	Randomized; compares investigational therapy to proven treatment; most likely to change practice

Phase 3 trials are testing new immunotherapies versus established first-line PD-1 treatment in patients with high PD-L1 to evaluate progression-free survival and other endpoints. The ROSETTA Lung-202 trial (NCT07361510), for example, compares an experimental agent versus pembrolizumab in previously untreated advanced NSCLC with PD-L1 ≥ 50%.

Common eligibility criteria

Most immunotherapy trials require:

ECOG performance status of 0 or 1 (able to carry out daily activities with minimal restriction)
Adequate organ function: liver, kidney, and bone marrow labs within defined ranges
Tumor molecular profiling: KRAS G12C, STK11, KEAP1, EGFR, ALK, and PD-L1 are commonly required. Rigorous biomarker screening is standard, and patients should request their full molecular profiling report proactively.
Prior treatment history: some trials require no prior systemic therapy (first-line); others require at least one prior line
No active autoimmune disease or conditions requiring systemic steroids

Biomarker-driven enrollment is the norm, not the exception. A trial for patients with KRAS G12C mutations, for instance, will screen out patients who do not carry that alteration regardless of other factors. Getting your molecular profiling report early, before you start searching, saves weeks.

Randomization is a reality in Phase 3 trials. Patients may be assigned to the investigational arm or the active comparator arm. Patients in the control arm receive the current standard of care, not a placebo, in the vast majority of lung cancer immunotherapy trials.

What does participating in a trial actually look like?

Knowing the rhythm of trial participation helps you and your caregiver plan realistically. Here is a typical sequence:

Screening period (2–4 weeks): Baseline labs, CT or PET imaging, tumor tissue submission, and eligibility confirmation. This is the most document-intensive phase.
Induction treatment (cycles 1–4, typically 21-day cycles): IV infusions at the trial site, often every 3 weeks. Labs are drawn before each cycle. Imaging is usually repeated at weeks 6 and 12.
Maintenance phase: After induction, many patients continue on a reduced regimen. Visit frequency often drops, but labs and imaging continue on a schedule.
Long-term follow-up: Some trials track patients for years. The ROSETTA Lung-201 trial (NCT07361497), for example, tracks patients for up to approximately 9 years to capture overall survival outcomes.

What monitoring looks like in practice:

Frequent blood draws (complete blood count, metabolic panel, thyroid function)
CT or MRI scans at defined intervals, evaluated by blinded independent reviewers in Phase 3 trials
Physical exams and vital signs at each visit
Patient-reported outcome questionnaires (symptoms, quality of life)
Adverse event reporting, which you initiate by contacting the trial team between visits

Immune-related side effects are the most important safety consideration in immunotherapy trials. These can affect the lungs (pneumonitis), liver, thyroid, skin, or colon. Trial teams are trained to detect them early. Treatment usually involves corticosteroids and a temporary hold on the study drug. Serious immune-related events are uncommon but require prompt reporting.

Side Effect Category	Common Examples	Typical Management
Pulmonary	Pneumonitis, cough, shortness of breath	Steroids, treatment hold
Endocrine	Thyroid dysfunction, adrenal insufficiency	Hormone replacement, monitoring
Gastrointestinal	Colitis, diarrhea	Steroids, dietary adjustment
Hepatic	Elevated liver enzymes	Steroids, dose modification
Skin	Rash, pruritus	Topical or systemic steroids

Caregiver involvement matters enormously during trial participation. Someone who can attend visits, track symptoms, and communicate with the trial team between appointments makes a measurable difference in how quickly problems are caught and addressed.

What do trials cost, and who pays?

This is one of the most practical questions, and the answer is more reassuring than most people expect.

What the trial sponsor typically covers:

The investigational drug itself
Protocol-mandated tests and procedures (labs, imaging required by the trial protocol)
Sometimes travel stipends or lodging assistance, depending on the sponsor and site

What your insurance typically covers:

Routine care costs: standard labs, office visits, and treatments your doctor would order regardless of trial participation
Most major insurers, including Medicare and Medicaid, are required by law to cover routine costs of care in qualifying clinical trials

Before you enroll, check these billing specifics:

Ask the trial coordinator for a written list of what the sponsor covers versus what will be billed to insurance
Contact your insurer to confirm coverage and request pre-authorization for any procedures flagged as potentially billable
Ask whether the trial site has a financial counselor who specializes in trial billing

Sources of financial and travel support:

Patient advocacy organizations, including the American Lung Association and the Cancer Research Institute, maintain lists of financial assistance programs
Cancer-center foundations often have funds for travel, lodging, and incidental costs
Some sponsors provide direct participant support, including transportation reimbursement

Pro Tip: Document every conversation with your insurer in writing. Note the date, the representative’s name, and what was confirmed. If a billing dispute arises later, that paper trail is your strongest asset.

Questions to ask the trial team and your oncologist

Print this list and bring it to your next appointment. These are the questions that matter most.

On eligibility and biomarkers:

Do I meet the eligibility criteria based on my current test results?
What additional tests do I need before pre-screening is complete?
Is my tumor molecular profiling report sufficient, or do I need a fresh biopsy?

On randomization and treatment:

What are the arms of this trial, and what would I receive in each?
If I am randomized to the control arm, what is the standard treatment I would receive?
Is there any crossover option if the investigational arm shows early benefit?

On logistics and commitment:

How often will I need to come in for visits and labs?
How long is the treatment phase, and how long is follow-up?
What happens if I need to miss a visit or travel?

On costs and support:

What does the sponsor cover, and what will be billed to my insurance?
Is there travel or lodging assistance available?
Who do I call if I experience a side effect between visits?

On post-trial access:

If the investigational drug works for me, can I continue receiving it after the trial ends?
What expanded access or compassionate use options exist if the trial closes?

How do you go from finding a trial to actually enrolling?

The path from “I found a trial” to “I am enrolled” has five clear steps. Moving through them quickly matters, because enrollment windows close.

Save the NCT number and contact the study coordinator. Every trial listing on clinicaltrials.gov includes a contact section. Call or email the study coordinator and ask for the pre-screening checklist. This tells you immediately whether you are likely eligible.
Gather your medical records and biomarker report. Provide your tumor molecular profiling results, recent imaging, pathology reports, and treatment history. Proactively requesting your biomarker report from your oncology team can shorten the eligibility review by weeks.
Complete the informed consent process. Before any trial-specific procedure begins, you will receive a detailed consent document. Read it carefully, especially the sections on procedures, risks, alternatives, and your right to withdraw at any time. Ask questions. Take the document home if you need time.
Complete baseline screening tests. Once consent is signed, the trial team orders baseline labs, imaging, and any required tumor tissue submissions. This phase typically takes 2–4 weeks.
Receive your first dose. If all screening criteria are met, you are formally enrolled and treatment begins. Your oncologist and the trial team should communicate directly throughout.

Pro Tip: You can be referred to a trial by your oncologist, or you can contact a trial site directly. Both paths are valid. If your current oncologist is not affiliated with a trial site, ask for a referral or contact the site yourself. You do not need permission to inquire.

Why comprehensive cancer centers matter, and how HCRF can help

Not all trial access is equal. Comprehensive cancer centers carry advantages that community oncology practices simply cannot replicate: larger trial portfolios, multidisciplinary tumor boards that review complex cases, on-site biomarker testing, and supportive care teams trained specifically in immunotherapy toxicity management.

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is one of the nation’s NCI-designated comprehensive cancer centers. It maintains an active portfolio of immunotherapy trials across lung cancer histologies and stages, with on-site molecular profiling and a team experienced in managing immune-related adverse events.

HCRF, the Hippocratic Cancer Research Foundation, is the nonprofit engine behind much of this work. As a 501©(3) organization, HCRF funds “out of the box” research at Robert H. Lurie Comprehensive Cancer Center, supports patient navigation, and helps patients and caregivers understand their options. HCRF’s role is not just fundraising. It is connection: connecting patients to trials, connecting caregivers to resources, and connecting donors to research that changes outcomes.

How HCRF can help you specifically:

Patient navigation support to help you interpret trial listings and understand eligibility
Guidance on requesting and reading your tumor molecular profiling report
Direct connection to the Robert H. Lurie Comprehensive Cancer Center trial teams
Educational resources, including guides on immunotherapy for prostate cancer and supplements to avoid during immunotherapy, that help you prepare for treatment

Pro Tip: If you are unsure whether your current oncologist has access to the trials you have found, ask HCRF. Navigation support exists precisely for moments like this, and it costs you nothing to reach out.

Key Takeaways

Immunotherapy clinical trials for lung cancer are open now across multiple stages and histologies in the U.S., and patients who request their biomarker report early and contact trial sites promptly have the widest range of options.

Point	Details
Trials are open now	Immunotherapy trials are actively recruiting for NSCLC across stages, including Stage III and metastatic disease.
Biomarker report is your key	Request tumor molecular profiling (PD-L1, KRAS G12C, EGFR, ALK, TMB) from your oncologist before searching trials.
Phase 3 follow-up can span years	Some trials, like ROSETTA Lung-201 (NCT07361497), include follow-up of up to approximately 9 years for overall survival, tracking long-term outcomes beyond the treatment phase.
Costs are often shared	Sponsors cover investigational drugs and protocol tests; insurance typically covers routine care costs in qualifying trials.
HCRF connects you to trials	The Hippocratic Cancer Research Foundation offers patient navigation and direct connection to Robert H. Lurie Comprehensive Cancer Center trial teams.

Why we believe every patient deserves a seat at the table

There is something we feel deeply at HCRF: the belief that access to the most promising cancer research should not depend on where you live, who your doctor is, or whether you knew to ask the right question at the right moment. Too many patients never hear about a trial that could have changed everything. That gap is not acceptable to us.

What we have seen, again and again, is that the patients who engage early, who ask their oncologist about trials at diagnosis rather than after two lines of treatment have failed, are the ones with the most options. The science is moving fast. Combination immunotherapy regimens that did not exist three years ago are now in Phase 3 trials. Biomarker-driven enrollment means that a specific mutation you carry could be the key that opens a door to a treatment designed precisely for your tumor’s biology.

We also want to say this plainly: trials are not experiments on people who have run out of hope. They are structured, rigorously monitored pathways to treatments that may become tomorrow’s standard of care. The oversight is real. The monitoring is intensive. And the community of researchers, navigators, and advocates working to make these trials accessible is larger and more committed than it has ever been.

We are proud to stand alongside patients and caregivers in this work. And we are here, whenever you are ready to reach out.

HCRF is here to help you find the right trial

The path from diagnosis to trial enrollment can feel long. We want to shorten it for you.

Hcrfwingstocure

The Hippocratic Cancer Research Foundation funds innovative immunotherapy research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and provides patient navigation support to help you find and access clinical trials. We can help you understand your biomarker report, identify trials that match your diagnosis and mutation profile, and connect you directly with the trial teams at Robert H. Lurie Comprehensive Cancer Center.

You do not have to figure this out alone. Reach out to HCRF today, and let us help you take the next step. Our team is ready to connect you with the resources, the researchers, and the trials that could matter most for your care.

Trusted registries and resources for verified trial listings

These are the sources we recommend you bookmark and return to regularly as your treatment journey evolves.

Trial registries:

clinicaltrials.gov: The U.S. federal registry for all clinical trials. Search by condition, phase, biomarker, and location. Save NCT numbers for every trial of interest.
NCI Lung Cancer Clinical Trials: Curated listings from the National Cancer Institute, organized by cancer type and treatment approach.
NCI NSCLC Treatment Trials: Specific to non-small cell lung cancer, with trial descriptions written for patients.

Advocacy and patient support:

American Lung Association: Provides trial-finding resources, lung cancer specialist connections, and patient support programs.
Cancer Research Institute: Offers patient-facing educational materials on immunotherapy approaches and supportive resources for trial participants.

HCRF resources:

Hippocratic Cancer Research Foundation: Patient navigation, trial-matching support, and connection to Robert H. Lurie Comprehensive Cancer Center.
Pancreatic cancer immunotherapy trial guide: An example of HCRF’s patient education work across cancer types.

News